Potassium iodide

Jump to: navigation, search
Potassium iodide
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Potassium iodide is an expectorant that is FDA approved for the treatment of of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema.. Common adverse reactions include stomach upset, diarrhea, nausea, vomiting, stomach pain, skin rash, and salivary gland swelling or tenderness, gastrointestinal bleeding, confusion.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

For use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema.

Dosage

  • Adults - 0.3 ml (300 mg) or 0.6 ml (600 mg) diluted in one glassful of water, fruit juice or milk 3 to 4 times daily. To minimize gastric irritation, take with food or milk.
  • This medication should be used no longer than necessary to produce the desired effect.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Potassium iodide in adult patients.

Non–Guideline-Supported Use

Indications and Dosage

  • Induction of involution of thyroid: 60-250 mg orally 3 times a day for 10 days before surgery.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Potassium iodide FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Potassium iodide in pediatric patients.

Non–Guideline-Supported Use

Indications and Dosage

  • Induction of involution of thyroid

Contraindications

  • Contraindicated in patients with a known sensitivity to iodides.

Warnings

  • Potassium iodide can cause fetal harm, abnormal thyroid function, and goiter when administered to a pregnant woman. Because of the possible development of fetal goiter, if the drug is used during pregnancy or if the patient becomes pregnant during therapy, apprise the patient of the potential hazard.

Adverse Reactions

Clinical Trials Experience

  • Iodism or chronic iodine poisoning may occur during prolonged treatment or with the use of high doses. The symptoms of iodism include burning of mouth or throat, severe headache, metallic taste, soreness of teeth and gums, symptoms of head cold, irritation of the eyes with swelling of the eyelids, unusual increase in salivation, acneform skin lesions in the seborrheic areas, and rarely, severe skin eruptions. If symptoms of iodism appear, the drug should be withdrawn and the patient given appropriate supportive therapy.

Postmarketing Experience

There is limited information regarding Potassium iodide Postmarketing Experience in the drug label.

Drug Interactions

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): Category D
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Potassium iodide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Potassium iodide during labor and delivery.

Nursing Mothers

Potassium iodide is excreted in breast milk. Use by nursing mothers may cause skin rash and thyroid suppression in the infant.

Pediatric Use

  • Safety and effectiveness in children have not been established.

Geriatic Use

There is no FDA guidance on the use of Potassium iodide in geriatric settings.

Gender

There is no FDA guidance on the use of Potassium iodide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Potassium iodide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Potassium iodide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Potassium iodide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Potassium iodide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Potassium iodide in patients who are immunocompromised.

Others

Administration and Monitoring

Administration

Oral

Monitoring

There is limited information regarding Potassium iodide Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Potassium iodide and IV administrations.

Overdosage

  • Acute toxicity from potassium iodide is relatively rare. An occasional individual may show marked sensitivity and the onset of acute poisoning can occur immediately or hours after administration. Angioedema, laryngeal edema and cutaneous hemorrhages may occur.
  • Iodism or chronic iodine poisoning may occur during prolonged treatment or with the use of high doses. Symptoms of iodism typically disappear soon after discontinuation of the drug. Abundant fluid and salt intake aids in iodide elimination.

Pharmacology

Potassium iodide
Potassium iodide.jpg
Potassium-iodide-3D-ionic.png
IUPAC name Potassium iodide
Identifiers
CAS number 7681-11-0
PubChem 4875
DrugBank DB06715
KEGG D01016
ChEBI 8346
RTECS number TT2975000
ATC code R05CA02,S01XA04, V03AB21
SMILES [K+].[I-]
InChI InChI=1/HI.K/h1H;/q;+1/p-1
Properties
Molecular formula KI
Molar mass 166.0028 g/mol
Appearance white crystalline solid
Density 3.123 g/cm3
Melting point

681 °C, 954 K, 1258 °F

Boiling point

1330 °C, 1603 K, 2426 °F

Solubility in water 128 g/100 ml (0 °C)
140 g/100 mL (20 °C)
176 g/100 mL (60°C)
206 g/100 mL (100°C)
Solubility 2 g/100 mL (ethanol)
soluble in acetone (1.31 g/100 mL)
slightly soluble in ether, ammonia
Refractive index (nD) 1.677
Viscosity 1.0227 cP (733 °C)
Structure
Crystal structure cubic
Thermochemistry
Std enthalpy of
formation
ΔfHo298
-327.6 kJ/mol
Standard molar
heat capacity
, cpo
52.73 J/mol K
Hazards
MSDS External MSDS
EU Index Not listed
NFPA 704

NFPA 704.svg

0
1
0
 
Related Compounds
Other anions Potassium fluoride
Potassium chloride
Potassium bromide
Other cations Lithium iodide
Sodium iodide
Rubidium iodide
Caesium iodide
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)

Infobox disclaimer and references

Mechanism of Action

  • Potassium iodide is thought to act as an expectorant by increasing respiratory tract secretions and thereby decreasing the viscosity of mucus.

Structure

There is limited information regarding Potassium iodide Structure in the drug label.

Pharmacodynamics

There is limited information regarding Potassium iodide Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Potassium iodide Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Potassium iodide Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Potassium iodide Clinical Studies in the drug label.

How Supplied

  • SSKI® (Potassium Iodide Oral Solution, USP) is supplied in 1 fluid ounce (30 ml) bottles (NDC 0245-0003-31) with a calibrated dropper marked to deliver 0.3 ml (300 mg) and 0.6 ml (600 mg); and 8 fluid ounce (237 ml) bottles (NDC 0245-0003-08). Inactive ingredient: Sodium thiosulfate as a preservative.

Dispense in tight, light-resistant containers with child-resistant closures.

Notice: When exposed to cold temperatures, crystallization may occur, but on warming and shaking, the crystals will redissolve. If the solution turns brownish-yellow in color, it should be discarded.

Storage

  • Store at controlled room temperature, 15-30°C (59-86°F). Keep tightly closed and protected from light.

Images

Drug Images

Package and Label Display Panel

Potassium iodide ingredients and appearance.png
This image of the FDA label is provided by the National Library of Medicine.
Potassium iodide fig01.jpg
This image of the FDA label is provided by the National Library of Medicine.

Patient Counseling Information

There is limited information regarding Potassium iodide Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Potassium iodide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

SSKI

Look-Alike Drug Names

There is limited information regarding Potassium iodide Look-Alike Drug Names in the drug label.

Drug Shortage Status

Drug Shortage

Price

References

The contents of this FDA label are provided by the National Library of Medicine.


Linked-in.jpg